Health · 17 July 2026

New global trial combines GLP-1 drugs and lifestyle to cut cognitive decline

The Alzheimer's Association revealed a new global trial, PROTECT-Cog, to investigate if GLP-1 drugs and lifestyle changes can lower cognitive decline risk in older adults. PROTECT-Cog builds on the US POINTER study, which showed lifestyle programmes gave up to two years of cognitive advantage. Researchers will monitor participants over three years to determine if the integrated strategy is more successful at postponing mild cognitive impairment.

By BriefTea Editorial · 17 July 2026 at 16:42

Reported by EMJ · How we write briefs

Get the app

More briefs

HealthCorrecting hearing loss can cut dementia risk by almost half HealthMan changes life after doctor warns liver disease could kill him HealthSweetener used in chewing gum and jam linked to strokes and heart attacks HealthMouth cancer rates up a third in UK, often with no obvious cause HealthBox breathing helps calm stress and reduce anxiety, say experts HealthNHS managers warn spiralling costs could disrupt ADHD and autism care More health stories → Browse all stories →